Solasia Pharma KK 4597.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4597.T. It has been listed since 24 March 2017. In the fiscal year to 31 December 2025, it reported revenue of ¥429.0m and a net loss of ¥876.0m. At that date it held total assets of ¥2.15bn and shareholders' equity of ¥1.75bn.

Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yoshihiro AraiPresident, Representative Director, since 2013
• Mr. Toshio MiyashitaChief Financial Officer, Chief Director of Administration, Director, since 2014
• Mr. Norikazu EikiIndependent Director
• Mr. Stanley LauIndependent Director
• Mr. Jiro MizukawaIndependent Director
• Mr. Yasumitsu ShimadaDirector of Accounting, since 2017

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.